Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX), a medical device company focusing on innovative technologies for nervous system diseases, has released a new CEO Corner segment. The segment, featuring CEO Brad Hauser, discusses the company's recent licensing agreement with RF Innovations for the intellectual property of the Apex 6 Radiofrequency Generator. This transaction marks a significant step in Autonomix's mission to revolutionize the diagnosis and treatment of nervous system disorders. The CEO Corner segment is now available on the company's website, providing investors and stakeholders with insights into this strategic move and its potential impact on Autonomix's future developments.
Positive
- Licensing agreement for Apex 6 Radiofrequency Generator intellectual property
- Strategic expansion of technology portfolio in nervous system disease treatment
Negative
- None.
THE WOODLANDS, TX, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Brad Hauser, CEO of Autonomix, discussed the Company’s recently completed transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Radiofrequency Generator.
The CEO Corner segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com
FAQ
What did Autonomix Medical (AMIX) announce on August 2, 2024?
Who is featured in Autonomix Medical's (AMIX) latest CEO Corner segment?
What recent transaction did Autonomix Medical (AMIX) complete with RF Innovations?
Where can investors find Autonomix Medical's (AMIX) new CEO Corner segment?
